Abstract Number: 2848 • 2017 ACR/ARHP Annual Meeting
Improving Gout Outcomes: The Randomized Evaluation of an Ambulatory Care Pharmacist-Led Intervention to Optimize Urate Lowering Pathways (RAmP-Up) Study
Background/Purpose: Allopurinol is a cornerstone therapy in gout management. Despite this, allopurinol use is suboptimal as providers often fail to follow the treat-to-target paradigm…Abstract Number: 2896 • 2017 ACR/ARHP Annual Meeting
Human Cartilage Influences the Crystallization of Monosodium Urate; Understanding the Link between Gout and Osteoarthritis
Background/Purpose: Monosodium urate (MSU) crystal deposition and gout flares frequently affect joints that have been damaged or are affected by osteoarthritis. The aim of…Abstract Number: 2898 • 2017 ACR/ARHP Annual Meeting
New Mouse Model of Gout Risk Variant, ABCG2 Q141K, Reveals Unexpectedly Severe Molecular and Functional Defect in ABCG2 Mediated Intestinal Uric Acid Secretion
Background/Purpose: Gout is a common arthritic disease resulting from deposition of monosodium urate crystals in joints and is a consequence of having elevated circulating uric…Abstract Number: 2950 • 2017 ACR/ARHP Annual Meeting
Validation of a Definition for Flare in Patients with Established Gout
Background/Purpose: A standardized validated definition for gout flares (or attacks) is not available. Two provisional definitions published in 2012 were based on patient-reported elements (patient-defined…Abstract Number: 2989 • 2017 ACR/ARHP Annual Meeting
Hydration and Gout: Looking at New Modes of Uric Acid Management
Background/Purpose: Gout affects more than 4% of adults in the United States, and it is the most common form of inflammatory arthritis among men. Studies…Abstract Number: 7L • 2016 ACR/ARHP Annual Meeting
Overall Reduction in Acute Flares during Treatment with Febuxostat Compared with Placebo over 2 Years in Patients with Early Gout
Background/Purpose: No clinical trials have previously investigated the frequency of acute flares in early gout or the benefit of instituting urate-lowering therapy (ULT) earlier in…Abstract Number: 75 • 2016 ACR/ARHP Annual Meeting
Genetic Analysis of Urate Transporters ABCG2, SLC17A3, SLC22A11 and SLC17A1 in Primary Hyperuricemia and Gout
Background/Purpose: The urate transporters are one of the genetic determinants of serum uric acid concentrations. In the present study, we describe the analysis of sequencing…Abstract Number: 161 • 2016 ACR/ARHP Annual Meeting
Are Ultrasound Definitions in Gout Reliable?: Preliminary Results from a Latin American Reliability Exercise
Background/Purpose: Although there is a consistent body of evidence supporting the use of Ultrasound (US) in Gout, several definitions for US lesions have been proposed.…Abstract Number: 194 • 2016 ACR/ARHP Annual Meeting
Pharmacokinetics, Pharmacodynamics, and Tolerability of Concomitant Multiple Dose Administration of Verinurad (RDEA3170) and Allopurinol in Adult Male Subjects with Gout
Background/Purpose: Verinurad (RDEA3170) is a novel selective uric acid reabsorption inhibitor in clinical development for the treatment of hyperuricemia and gout. This Phase 1, single-blind,…Abstract Number: 195 • 2016 ACR/ARHP Annual Meeting
Pharmacodynamics, Pharmacokinetics, and Safety of Verinurad in Combination with Febuxostat Versus Febuxostat Alone and Verinurad Alone in Japanese Adults with Gout or Asymptomatic Hyperuricemia: A Phase 2a, Open-Label Study
Background/Purpose: Verinurad (RDEA3170) is a high-affinity URAT1 inhibitor in development for the treatment of gout and asymptomatic hyperuricemia. This Phase 2a, randomized, open-label, single-site study…Abstract Number: 196 • 2016 ACR/ARHP Annual Meeting
Pharmacodynamic Effects and Safety of Verinurad in Combination with Allopurinol Versus Allopurinol Alone in Adults with Gout: A Phase 2a, Open-Label Study
Background/Purpose: Verinurad (RDEA3170) is a high-affinity, selective URAT1 inhibitor in development for treatment of gout and asymptomatic hyperuricemia. This Phase 2a, randomized, open-label, multicenter study…Abstract Number: 197 • 2016 ACR/ARHP Annual Meeting
Pharmacodynamic Effects and Safety of Verinurad in Combination with Febuxostat Versus Febuxostat Alone in Adults with Gout: A Phase 2a, Open-Label Study
Background/Purpose: Verinurad (RDEA3170) is a high-affinity, selective URAT1 inhibitor in development for treatment of gout and asymptomatic hyperuricemia. This Phase 2a, randomized, open-label, multicenter study…Abstract Number: 198 • 2016 ACR/ARHP Annual Meeting
A Phase 2 Study to Evaluate the Efficacy and Safety of Febuxostat Extended- Versus Immediate-Release Formulations in Patients with Gout and Moderate Renal Impairment
Background/Purpose: Data generated by Phase 1 and 2 studies suggest that the extended-release (XR) formulation of febuxostat (FBX) may provide equal or better reduction in…Abstract Number: 199 • 2016 ACR/ARHP Annual Meeting
A Phase 3 Study to Evaluate the Efficacy and Safety of Febuxostat Extended- Versus Immediate-Release Formulations in Patients with Gout
Background/Purpose: Data generated by Phase 1 and 2 studies suggest that the extended-release (XR) formulation of febuxostat (FBX) may provide equal or better reduction in…Abstract Number: 200 • 2016 ACR/ARHP Annual Meeting
The Safety and Efficacy of Benzbromarone in Gout in Aotearoa New Zealand
Background/Purpose: Benzbromarone is a potent uricosuric, but is not widely available due to concerns about hepatotoxicity. In Aotearoa New Zealand benzbromarone has been available since…
Simple Search Results
Didn't find what you were looking for? Try the Advanced Search »
Didn't find what you were looking for? Try the Advanced Search »